Drug intelligence / Profile preview

GHX02

Development stage: Phase 2
Lead developer: Daejeon University
Administration: Oral

Overview

GHX02 is a herbal formulation containing four herbs: Trichosanthis semen (Gwaruin), Armeniacae semen (Haengin), Coptidis rhizoma (Hwangryeon), and Scutellariae radix (Hwanggeum). It has been clinically used for bronchitis at Daejeon Korean Medicine Hospital in South Korea. Preclinical studies have shown that GHX02 reduces airway inflammation, sputum production, cough, suppresses PM10D-induced inflammatory symptoms in the lung, and has anti-COPD effects. It also inhibits the production of inflammatory cytokines and has antioxidant effects.

Beyond the preview

Go deeper on GHX02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GHX02.

Explore the full profile